Fig. (2) The PKR activation block is not unique to CypI, DAAs
also prevent the IFN-induced PKR activation in HCV-infected
cells. Same as (Fig. 1c) except that JFH-1-infected Huh7.5.1 cells
were treated with or without CypI (cyclosporine A and alisporivir),
DAAs (the HCV NS5A inhibitor daclatasvir and the HCV protease
inhibitor telaprevir) and an HIV-1 inhibitor (reverse transcriptase
inhibitor emtricitabine). Results are representative of 4 independent
experiments.